Cyclosporin A and Misoprostol Combination

Cyclosporin A (also known as cyclosporine) is a calcineurin inhibitor that functions as a potent immunosuppressant, primarily used in organ transplantation to prevent rejection. It works by inhibiting T cell activation through binding to cyclophilin-1, forming a complex that inhibits calcineurin. This prevents the dephosphorylation and activation of nuclear factor of activated T cells (NF-AT), thereby reducing the production of inflammatory cytokines like IL-2, IL-4, interferon-gamma, and TNF-alpha[1][5]. Misoprostol is a synthetic prostaglandin E1 analog that reduces stomach acid and protects the stomach lining from damage caused by NSAIDs. When used in combination with cyclosporin A, misoprostol has been shown to prevent chronic cyclosporin A-induced nephrotoxicity, which is a significant side effect of cyclosporin A therapy[2][6]. Studies have demonstrated that misoprostol can improve renal function in renal transplant patients treated with cyclosporine and prednisone. In one clinical study, misoprostol 200 mcg administered four times daily for the first 12 weeks after transplantation significantly reduced the incidence of acute rejection (26% vs 51% in the control group). Although not statistically significant, there was a higher incidence of cyclosporine nephrotoxicity in the misoprostol group[6]. The combination is particularly valuable in transplant patients, as cyclosporin A's renal toxicity and hypertension can pose significant management challenges. Research has attributed this toxicity to prostaglandin inhibition, which misoprostol can help counteract[2].

Other names

Cyclosporine and Misoprostol